BRISTOL-MYERS SQUIBB COMPANY Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.00% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-13.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2024-02-13
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 0.00%.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was 0.00%.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -1.30%, a 124.53% decline from fiscal 2020.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was 5.30%, a 140.91% increase from fiscal 2019.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2023-12-31 | 0.00% 10-K · filed 2024-02-13 |
| 2022-12-31 | 0.00% 10-K · filed 2024-02-13 |
| 2021-12-31 | -1.30% 10-K · filed 2024-02-13 |
| 2020-12-31 | 5.30% 10-K · filed 2023-02-14 |
| 2019-12-31 | 2.20% 10-K · filed 2022-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |